These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34849724)

  • 21. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials.
    Naci H; Brugts JJ; Fleurence R; Ades AE
    Eur J Prev Cardiol; 2013 Aug; 20(4):658-70. PubMed ID: 23529608
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
    Izquierdo-Palomares JM; Fernandez-Tabera JM; Plana MN; Añino Alba A; Gómez Álvarez P; Fernandez-Esteban I; Saiz LC; Martin-Carrillo P; Pinar López Ó
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD009462. PubMed ID: 27888640
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
    Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
    Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statins for the primary prevention of cardiovascular disease.
    Taylor F; Ward K; Moore TH; Burke M; Davey Smith G; Casas JP; Ebrahim S
    Cochrane Database Syst Rev; 2011 Jan; (1):CD004816. PubMed ID: 21249663
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Dana T; Blazina I; Daeges M; Jeanne TL
    JAMA; 2016 Nov; 316(19):2008-2024. PubMed ID: 27838722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins.
    Naci H; Dias S; Ades AE
    BMJ; 2014 Oct; 349():g5741. PubMed ID: 25281681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy.
    Lorenzi M; Ambegaonkar B; Baxter CA; Jansen J; Zoratti MJ; Davies G
    Clin Res Cardiol; 2019 May; 108(5):487-509. PubMed ID: 30302558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Switching From Statin Monotherapy to Ezetimibe/Simvastatin Combination Therapy Compared With Other Intensified Lipid-Lowering Strategies on Lipoprotein Subclasses in Diabetic Patients With Symptomatic Cardiovascular Disease.
    Le NA; Tomassini JE; Tershakovec AM; Neff DR; Wilson PW
    J Am Heart Assoc; 2015 Oct; 4(10):e001675. PubMed ID: 26486166
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk?
    Reiner Ž
    Curr Atheroscler Rep; 2019 Mar; 21(4):14. PubMed ID: 30847681
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic efficacy of PCSK9 monoclonal antibodies in statin-nonresponsive patients with hypercholesterolemia and dyslipidemia: A systematic review and meta-analysis.
    Peng W; Qiang F; Peng W; Qian Z; Ke Z; Yi L; Jian Z; Chongrong Q
    Int J Cardiol; 2016 Nov; 222():119-129. PubMed ID: 27494723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels: A Meta-analysis.
    Sabatine MS; Wiviott SD; Im K; Murphy SA; Giugliano RP
    JAMA Cardiol; 2018 Sep; 3(9):823-828. PubMed ID: 30073316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
    Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
    Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy.
    Mikhailidis DP; Sibbring GC; Ballantyne CM; Davies GM; Catapano AL
    Curr Med Res Opin; 2007 Aug; 23(8):2009-26. PubMed ID: 17659159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN.
    Puri R; Ballantyne CM; Hoogeveen RC; Shao M; Barter P; Libby P; Chapman MJ; Erbel R; Arsenault BJ; Raichlen JS; Nissen SE; Nicholls SJ
    Atherosclerosis; 2017 Aug; 263():137-144. PubMed ID: 28641153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipoprotein(a): A Concealed Precursor of Increased Cardiovascular Risk? A Real-World Regional Lipid Clinic Experience.
    Anastasiou G; Sakka E; Blathra E; Kalivi A; Elisaf M; Liamis G; Liberopoulos E
    Arch Med Res; 2021 May; 52(4):397-404. PubMed ID: 33380360
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elevated Lipoprotein(a) as a potential residual risk factor associated with lipid-rich coronary atheroma in patients with type 2 diabetes and coronary artery disease on statin treatment: Insights from the REASSURE-NIRS registry.
    Nakamura H; Kataoka Y; Nicholls SJ; Puri R; Kitahara S; Murai K; Sawada K; Matama H; Iwai T; Honda S; Fujino M; Takagi K; Yoneda S; Otsuka F; Nishihira K; Asaumi Y; Tsujita K; Noguchi T
    Atherosclerosis; 2022 May; 349():183-189. PubMed ID: 35450750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.